News | Image Guided Radiation Therapy (IGRT) | August 21, 2017

Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System

Freestanding center is first in the western U.S. to treat patients with this "smart" radiation therapy delivery system with fully integrated treatment planning and data management systems

Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System

August 21, 2017 — Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact Treatment Delivery System, the next-generation TomoTherapy platform. The Radixact System replaced a competitive conventional linear accelerator in the single-vault freestanding facility.

The system provides precise and accurate treatments for more routine radiation therapy indications including skin, central nervous system, breast, head and neck, lung, prostate, gynecologic and gastrointestinal malignancies, in addition to more complex treatments such as craniospinal and total marrow irradiation. Additionally, Summit Cancer Center-Boise has the ability to perform stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).

"At Summit Cancer Center-Boise our goal is to use innovative technology to provide our patients with the treatment best suited to their needs. This system allows us to provide precise, individualized treatment while sparing normal tissues and maintaining optimal treatment efficacy," said John E. Gamboa, M.D., radiation oncologist, medical director of Summit Cancer Center-Boise.

The use of radiation as part of cancer treatment is increasing, both during initial treatment and increasingly for re-treatment, so the ability to deliver the correct dose precisely to the tumor is becoming even more important. The Radixact System was designed to deliver image-guided intensity-modulated radiation therapy, an extremely precise form of radiation therapy.

  • The system is built on a ring gantry platform with a computed tomography (CT) scanner. It provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles, ensuring the most precise treatment customized for each patient, minimizing exposure to healthy tissue and measurably mitigating side effects;
  • Treatment accuracy is achieved through daily 3-D image guidance, which ensures proper patient positioning and dose targeting even when anatomical changes occur. The system takes an image of the patient every day as part of the patient setup, enabling the clinical team to know exactly where the tumor is on that particular day;
  • The ultra-fast binary multileaf collimator (MLC) is a key component of the system, enabling it to deliver dose with extremely high precision and accuracy;
  • Continuous couch motion through the bore of the ring gantry facilitates seamless delivery to multiple targets or long volumes with no need for field matching, which would be required if using a conventional delivery device. This innovation in workflow also improves treatment quality by ensuring that highly-sculpted radiation doses can be delivered to tumors located anywhere in the body, regardless of the tumor size or the number of tumors receiving treatment;
  • A fully-integrated, simplified adaptive treatment planning solution, PreciseART Adaptive Radiation Therapy software, enables the clinical team to adjust therapy to changes in tumor size, shape and location — as well as subtle changes in the location of organs and other healthy tissue; and
  • The PreciseRTX Retreatment Option makes it easier for clinicians to deliver precise doses of radiation in those cases where, unfortunately, cancer has recurred and retreatment with radiation is necessary.

For more information: www.accuray.com

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init